b'IGH MRD Clonality AssaysBackgroundCombinations of chemotherapy, radiation therapy and(IGH) locus become rearranged through the random bone marrow transplantation are potentially curativedeletion or insertion of nucleotides within the junctional for several hematologic malignancies. However, in someregion, generating specific and unique sequences within patients, occult tumor cells exist and are thought to increaseeach lymphocyte. Cancer cells that arise from alterations the patients risk of relapse. 1These subclinical levels ofin single lymphoid precursors acquire clonal IGH junctional residual leukemia are termed minimal residual diseaseregions, which can be used as tumor-specific markers. 2-3(MRD) and can be evaluated using more sensitive assays.The tracking of antigen-receptor gene rearrangementsMRD detection by Next-Generation Sequencing has for clonality analyses and MRD monitoring can be applieddemonstrated utility in predicting clinical outcomes to virtually all patients. During early B-cell development,and in generating clinically actionable results, allowing the germline variable (V H ), diverse (D H ), and joining (J H )early intervention, confirmation of disease status prior to fragments of the human immunoglobulin heavy chaintransplant, and increased confidence in remission status. References1. Rezuke WN et al. (1997) Molecular diagnosis of B- and T-cell lymphomas: fundamental principles and clinical applications. Clin Chem 43:1814-23.2.Gazzola A et al. (2014) The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies. TherAdv Hematol. 5:35-47.3.Gonzlez D et al. (2007) Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 110:3112-21. 40'